Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.Read Article
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVIDRead Article
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.Read Article
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.Read Article
Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.Read Article
Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden inRead Article
Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.
This surveillance study examinedRead Article
Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.Read Article
In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) shared its perspective on the CY 2022 Medicare Physician Fee Schedule and Quality Payment Program proposed rule.
Rheumatology leaders are encouraged byRead Article
A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.
Data was collected from 592,571 individualsRead Article
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.
This prospective observational study used data from the STOP-JIA trial (Start Time Optimization ofRead Article
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
This retrospective analysis assessed treatment patterns among patients newly initiated on biologicRead Article
This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.Read Article
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.
Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53Read Article
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.
In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for
Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.
A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time.
A retrospective, population-based cohort examined incident adult PsARead Article
Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article. So many big names and yet, other names and stories that were equally inspirational.
If you read the comments of the part I article you can clearly see several themes emerge.Read Article